NCT05616624 2026-04-15
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers
Washington University School of Medicine
Phase 1/2 Active not recruiting
Clinical Trials
35 trialsNCT03970447 2026-04-08
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT06085729 2026-04-02
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05813327 2026-03-17
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
Washington University School of Medicine
Phase 1 Active not recruiting
NCT07389278 2026-02-05
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
NCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
NCT03449901 2025-12-11
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT05712694 2025-07-17
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Polaris Group
Phase 3 Recruiting
NCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06006286 2024-08-26
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT06034977 2023-09-13
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT04965714 2023-02-16
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00520299 2022-10-25
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01266018 2022-10-25
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Ludwig Institute for Cancer Research
Phase 2 Terminated
NCT03254732 2022-04-27
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Polaris Group
Phase 1 Terminated
NCT02102022 2022-04-25
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Polaris Group
Phase 1/2 Terminated
NCT01910012 2020-10-01
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Polaris Group
Phase 2 Completed
NCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT02875093 2020-03-05
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Polaris Group
Phase 1 Terminated
NCT03498222 2020-02-25
iTRAP
Queen Mary University of London
Phase 1 Withdrawn
NCT01287585 2019-09-06
ADI-PEG 20
Polaris Group
Phase 3 Completed
NCT01910025 2018-09-18
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Polaris Group
Phase 2 Completed
NCT01497925 2018-09-13
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
Polaris Group
Phase 1 Completed
NCT02006030 2018-09-04
TACE
Polaris Group
Phase 2 Completed
NCT00450372 2017-02-08
Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
University of Miami
Phase 2 Completed
NCT01948843 2016-04-14
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Polaris Group
Phase 1 Completed
NCT02101593 2016-03-04
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
Phase 1 Completed
NCT01665183 2016-02-25
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
Phase 1 Completed
NCT00029900 2015-03-25
ADI-PEG in Patients With Metastatic Melanoma
FDA Office of Orphan Products Development
Phase 1 Completed
NCT00056992 2015-03-25
Testing of ADI-PEG in Hepatocellular Carcinoma
FDA Office of Orphan Products Development
Phase 2 Completed
NCT01279967 2014-11-20
ADAM
Barts & The London NHS Trust
Phase 2 Unknown